UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly

Molecular cell, 2005-02, Vol.17 (4), p.525-535

2005

Volltextzugriff (PDF)

Abstract 5549: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5549-5549

2020

Volltextzugriff (PDF)

The Multidomain Proapoptotic Molecules Bax and Bak Are Directly Activated by Heat

Proceedings of the National Academy of Sciences - PNAS, 2005-12, Vol.102 (50), p.17975-17980

2005

Volltextzugriff (PDF)

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy

Frontiers in pharmacology, 2024-06, Vol.15, p.1380000

2024

Volltextzugriff (PDF)

Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death

Molecular biology of the cell, 2006-05, Vol.17 (5), p.2150-2157

2006

Volltextzugriff (PDF)

1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1167-A1167

2023

Volltextzugriff (PDF)

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100075-100075, Article 100075

2021

Volltextzugriff (PDF)

1193 Synergistic targeting of multiple activating pathways with natural killer cell engagers

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1315-A1315

2023

Volltextzugriff (PDF)

787 Natural killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A822-A822

2021

Volltextzugriff (PDF)

698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A726-A726

2021

Volltextzugriff (PDF)

564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A598-A598

2020

Volltextzugriff (PDF)

697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A739-A739

2020

Volltextzugriff (PDF)

714 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A756-A756

2020

Volltextzugriff (PDF)

The machinery of programmed cell death

Pharmacology & therapeutics (Oxford), 2001-10, Vol.92 (1), p.57-70

2001

Volltextzugriff (PDF)

A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies

Molecular cancer therapeutics, 2024-11, p.OF1-OF14

2024

Volltextzugriff (PDF)

Abstract 1743: IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1743-1743

2021

Volltextzugriff (PDF)

Abstract 1880: PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1880-1880

2021

Volltextzugriff (PDF)

Abstract 2286: XmAb30819, an XmAb®2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2286-2286

2020

Volltextzugriff (PDF)

Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5663-5663

2020

Volltextzugriff (PDF)

Moloney Murine Leukemia Virus-Induced Preleukemic Thymic Atrophy and Enhanced Thymocyte Apoptosis Correlate with Disease Pathogenicity

Journal of Virology, 1999-03, Vol.73 (3), p.2434-2441

1999

Volltextzugriff (PDF)

Regulatory T Cell Selective IL-2-Fc Fusion Proteins for the Treatment of Autoimmune Diseases

Blood, 2018-11, Vol.132 (Supplement 1), p.3709-3709

2018

Volltextzugriff (PDF)

Abstract 1860: Bispecific claudin-6 x CD3 antibodies in a 2 + 1 format demonstrate selectivity and activity on human ovarian cancer cells

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1860-1860

2021

Volltextzugriff (PDF)

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor

Arthritis & rheumatology (Hoboken, N.J.), 2014-05, Vol.66 (5), p.1153-1164

2014

Volltextzugriff (PDF)

Abstract 1595: IL15/IL15Rα heterodimeric Fc-fusions with extended half-lives

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1595-1595

2017

Volltextzugriff (PDF)

Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5565-5565

2018

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(11)
Immunotherapy
(8)
Apoptosis
(7)
Artificial Intelligence
(6)
Computer Science
(6)
Game Theory
(6)
Humans
(6)
Animals
(5)
Computer Science, Artificial Intelligence
(5)
Cytokines
(5)
Mice
(5)
Technology
(5)
Antibodies
(4)
Cytochromes C - Metabolism
(4)
Lymphocytes
(4)
Regular And Young Investigator Award Abstracts
(4)
Antigens
(3)
Cytotoxicity
(3)
Female
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly

Abstract 5549: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity

The Multidomain Proapoptotic Molecules Bax and Bak Are Directly Activated by Heat

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy

Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death

1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

1193 Synergistic targeting of multiple activating pathways with natural killer cell engagers

787 Natural killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines

698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents

697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

714 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors

The machinery of programmed cell death

A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies

Abstract 1743: IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents

Abstract 1880: PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

Abstract 2286: XmAb30819, an XmAb®2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies

Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models

Moloney Murine Leukemia Virus-Induced Preleukemic Thymic Atrophy and Enhanced Thymocyte Apoptosis Correlate with Disease Pathogenicity

Regulatory T Cell Selective IL-2-Fc Fusion Proteins for the Treatment of Autoimmune Diseases

Abstract 1860: Bispecific claudin-6 x CD3 antibodies in a 2 + 1 format demonstrate selectivity and activity on human ovarian cancer cells

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor

Abstract 1595: IL15/IL15Rα heterodimeric Fc-fusions with extended half-lives

Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure

Suchergebnisse filtern